You are here: Home » Companies » News
Business Standard

Patent infringement: Lupin's arm to pay damages to Bayer

An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals

Veena Mani  |  New Delhi 

Lupin

The Federal Court of Australia has ruled against major Lupin’s Australian arm, Generic Health, in a case with

In the order, the Australian court has asked to pay an amount of A$30 million to for causing loss of revenue. Bayer had sued for infringement of its patent for a contraceptive called Yasmin.

did not respond to queries sent by Business Standard.

Bayer, which markets a contraceptive called Yasmin, had alleged that violated the patent by marketing Isabelle. The court observed that for Bayer, every sale of Isabelle led to a loss of sale of Yasmin. The company sought only damages against seeking a portion of the profits made by the company on the sale of Isabelle in the Australian market. Bayer’s initial suit against was for infringement of its Australian patent, for sale of competing product Isabelle. However, during the proceedings in 2012, Bayer amended the claims of the patent.

Global portal for patent Lexology.com calls this decision “landmark”. It says, “This sets a new benchmark in Australia for future damages claims against generic manufacturers.  The court’s willingness to adequately compensate the patent holder enhances Australia’s already very attractive “value proposition” for patentees.” acquired majority stake in in 2010. This acquisition gave it access to the Australian pharmaceutical market.

This is not the first case where is entangled in a case. Soon after the company finished the acquisition of US-based Gavis pharmaceuticals, last year, Horizon Pharmaceuticals filed a case against the company for filing an Abbreviated New Drug Application (ANDA) for a generic version of Pennsaid, an anti-inflammatory non-steroidal drug. Horizon filed a case against the Mumbai-headquartered pharmaceutical company in the District Court of New Jersey.

A number of cases have been filed against leading Indian pharmaceutical and their counterparts in other countries over the last few years. A number of them have been in the United States of America. The list includes Dr Reddy’s Laboratories, Aurobindo Pharmaceuticals, Aurobindo Pharmaceutical’s US counterpart and, Bengaluru-based Biocon.

Indian pharmaceutical have been facing intense pressure on account of anti-trust cases too in the US. Recent cases include investigation into leading such as Sun Pharmaceuticals, Dr Reddy’s Laboratories among others.

RECOMMENDED FOR YOU

Patent infringement: Lupin's arm to pay damages to Bayer

An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals

An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals
The Federal Court of Australia has ruled against major Lupin’s Australian arm, Generic Health, in a case with

In the order, the Australian court has asked to pay an amount of A$30 million to for causing loss of revenue. Bayer had sued for infringement of its patent for a contraceptive called Yasmin.

did not respond to queries sent by Business Standard.

Bayer, which markets a contraceptive called Yasmin, had alleged that violated the patent by marketing Isabelle. The court observed that for Bayer, every sale of Isabelle led to a loss of sale of Yasmin. The company sought only damages against seeking a portion of the profits made by the company on the sale of Isabelle in the Australian market. Bayer’s initial suit against was for infringement of its Australian patent, for sale of competing product Isabelle. However, during the proceedings in 2012, Bayer amended the claims of the patent.

Global portal for patent Lexology.com calls this decision “landmark”. It says, “This sets a new benchmark in Australia for future damages claims against generic manufacturers.  The court’s willingness to adequately compensate the patent holder enhances Australia’s already very attractive “value proposition” for patentees.” acquired majority stake in in 2010. This acquisition gave it access to the Australian pharmaceutical market.

This is not the first case where is entangled in a case. Soon after the company finished the acquisition of US-based Gavis pharmaceuticals, last year, Horizon Pharmaceuticals filed a case against the company for filing an Abbreviated New Drug Application (ANDA) for a generic version of Pennsaid, an anti-inflammatory non-steroidal drug. Horizon filed a case against the Mumbai-headquartered pharmaceutical company in the District Court of New Jersey.

A number of cases have been filed against leading Indian pharmaceutical and their counterparts in other countries over the last few years. A number of them have been in the United States of America. The list includes Dr Reddy’s Laboratories, Aurobindo Pharmaceuticals, Aurobindo Pharmaceutical’s US counterpart and, Bengaluru-based Biocon.

Indian pharmaceutical have been facing intense pressure on account of anti-trust cases too in the US. Recent cases include investigation into leading such as Sun Pharmaceuticals, Dr Reddy’s Laboratories among others.



image
Business Standard
177 22

Patent infringement: Lupin's arm to pay damages to Bayer

An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals

The Federal Court of Australia has ruled against major Lupin’s Australian arm, Generic Health, in a case with

In the order, the Australian court has asked to pay an amount of A$30 million to for causing loss of revenue. Bayer had sued for infringement of its patent for a contraceptive called Yasmin.

did not respond to queries sent by Business Standard.

Bayer, which markets a contraceptive called Yasmin, had alleged that violated the patent by marketing Isabelle. The court observed that for Bayer, every sale of Isabelle led to a loss of sale of Yasmin. The company sought only damages against seeking a portion of the profits made by the company on the sale of Isabelle in the Australian market. Bayer’s initial suit against was for infringement of its Australian patent, for sale of competing product Isabelle. However, during the proceedings in 2012, Bayer amended the claims of the patent.

Global portal for patent Lexology.com calls this decision “landmark”. It says, “This sets a new benchmark in Australia for future damages claims against generic manufacturers.  The court’s willingness to adequately compensate the patent holder enhances Australia’s already very attractive “value proposition” for patentees.” acquired majority stake in in 2010. This acquisition gave it access to the Australian pharmaceutical market.

This is not the first case where is entangled in a case. Soon after the company finished the acquisition of US-based Gavis pharmaceuticals, last year, Horizon Pharmaceuticals filed a case against the company for filing an Abbreviated New Drug Application (ANDA) for a generic version of Pennsaid, an anti-inflammatory non-steroidal drug. Horizon filed a case against the Mumbai-headquartered pharmaceutical company in the District Court of New Jersey.

A number of cases have been filed against leading Indian pharmaceutical and their counterparts in other countries over the last few years. A number of them have been in the United States of America. The list includes Dr Reddy’s Laboratories, Aurobindo Pharmaceuticals, Aurobindo Pharmaceutical’s US counterpart and, Bengaluru-based Biocon.

Indian pharmaceutical have been facing intense pressure on account of anti-trust cases too in the US. Recent cases include investigation into leading such as Sun Pharmaceuticals, Dr Reddy’s Laboratories among others.



image
Business Standard
177 22